NCT00225524已完成3 期
Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression
Wyeth is now a wholly owned subsidiary of Pfizer73 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2004年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 73
- 主要终点
- Incidence of adverse events
研究概览
简要总结
Phase III long-term safety study of Effexor XR in patients with major depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)
排除标准
- •Patients with schizophrenia or any other psychotic disorder
- •Patients with history or presence of bipolar disorder
结局指标
主要结局
Incidence of adverse events
次要结局
- Quantitative data for laboratory data
研究者
研究点 (73)
Loading locations...
相似试验
已完成
3 期
Study Evaluating Effexor XR in Elderly Patients With Major Depression.DepressionNCT00225485Wyeth is now a wholly owned subsidiary of Pfizer100
已完成
3 期
Study Evaluating Effexor XR for Major Depression.DepressionNCT00225511Wyeth is now a wholly owned subsidiary of Pfizer590
撤回
4 期
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive DisorderMajor Depressive DisorderNCT00878748Wyeth is now a wholly owned subsidiary of Pfizer
已完成
3 期
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCystic FibrosisNCT04058366Vertex Pharmaceuticals Incorporated251
终止
3 期
Phase III Long-Term Extension Study With DexpramipexoleEosinophilic AsthmaNCT06388889Areteia Therapeutics509